Clinical Trial Update: BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations [Phase 1]

View source ↗

Summary

Phase 1 study of vemurafenib in pediatric patients with stage IIIC or stage IV BRAFV600-mutated melanoma was terminated; results were posted in July 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Vemurafenib (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Malignant Melanoma | Phase 1 | Status: TERMINATED | Results posted: 2016-07-28